Search details
1.
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Cell
; 171(2): 481-494.e15, 2017 Oct 05.
Article
in English
| MEDLINE | ID: mdl-28985567
2.
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Blood
; 143(5): 404-416, 2024 Feb 01.
Article
in English
| MEDLINE | ID: mdl-37890149
3.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
N Engl J Med
; 386(7): 640-654, 2022 02 17.
Article
in English
| MEDLINE | ID: mdl-34891224
4.
Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.
Haematologica
; 109(3): 857-866, 2024 Mar 01.
Article
in English
| MEDLINE | ID: mdl-37646670
5.
Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study.
Oncologist
; 28(10): e930-e941, 2023 10 03.
Article
in English
| MEDLINE | ID: mdl-37141401
6.
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.
Blood
; 137(10): 1318-1326, 2021 03 11.
Article
in English
| MEDLINE | ID: mdl-32992341
7.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
J Natl Compr Canc Netw
; 21(11): 1118-1131, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37935098
8.
Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
Future Oncol
; 19(1): 19-28, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36651471
9.
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Lancet Oncol
; 23(8): 1066-1077, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35839786
10.
Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis.
J Biol Chem
; 296: 100100, 2021.
Article
in English
| MEDLINE | ID: mdl-33208460
11.
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.
J Natl Compr Canc Netw
; 20(4): 322-334, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35390768
12.
De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients.
Transpl Infect Dis
; 24(6): e13914, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-35899968
13.
CAR T-cell therapy for relapsed/refractory non-Hodgkin's lymphoma: a comprehensive review.
Clin Adv Hematol Oncol
; 20(5): 309-318, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35579590
14.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Lancet
; 396(10254): 839-852, 2020 09 19.
Article
in English
| MEDLINE | ID: mdl-32888407
15.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
J Natl Compr Canc Netw
; 19(11): 1218-1230, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34781267
16.
Cardiovascular Toxicities of CAR T-cell Therapy.
Curr Oncol Rep
; 23(7): 78, 2021 05 03.
Article
in English
| MEDLINE | ID: mdl-33937946
17.
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(6): 755-781, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32502987
18.
Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma.
Nanomedicine
; 30: 102290, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32798731
19.
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
J Natl Compr Canc Netw
; 17(6): 650-661, 2019 06 01.
Article
in English
| MEDLINE | ID: mdl-31200358
20.
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
Cancer
; 124(1): 136-144, 2018 01 01.
Article
in English
| MEDLINE | ID: mdl-28902390